Generate Biomedicines Stock Forecast

Stock Price Forecast

The 4 analysts that cover Generate Biomedicines stock have a consensus rating of "Strong Buy" and an average price target of $25, which forecasts a 117.20% increase in the stock price over the next year. The lowest target is $20 and the highest is $30.

Price Target: $25 (+117.20%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$20	$25	$26	$30
Change	+73.76%	+117.20%	+125.89%	+160.64%

Analyst Ratings

The average analyst rating for Generate Biomedicines stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Mar '26
Strong Buy	2
Buy	3
Hold	0
Sell	0
Strong Sell	0
Total	5

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Salveen Richter Goldman Sachs	Goldman Sachs	Strong Buy Initiates $26	Strong Buy	Initiates	$26	+125.89%	Mar 24, 2026
Sean Laaman Morgan Stanley	Morgan Stanley	Buy Initiates $20	Buy	Initiates	$20	+73.76%	Mar 24, 2026
Edward Tenthoff Piper Sandler	Piper Sandler	Buy Initiates $24	Buy	Initiates	$24	+108.51%	Mar 24, 2026
Eric Schmidt Cantor Fitzgerald	Cantor Fitzgerald	Buy Initiates n/a	Buy	Initiates	n/a	n/a	Mar 24, 2026
Seamus Fernandez Guggenheim	Guggenheim	Strong Buy Initiates $30	Strong Buy	Initiates	$30	+160.64%	Mar 24, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

n/a

EPS Next Year

n/a

No financial forecasts available for this stock

Revenue Forecast

No data available

Revenue Growth

No data available

EPS Forecast

No data available

EPS Growth

No data available

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.